Glenmark Life Sciences Limited

BSE:543322 Stock Report

Mkt Cap: ₹47.9b

We’ve recently updated our valuation analysis.

Glenmark Life Sciences Valuation

Is 543322 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 543322?

Other financial metrics that can be useful for relative valuation.

543322 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.2x
Enterprise Value/EBITDA7.7x
PEG Ratio0.8x

Price to Earnings Ratio vs Peers

How does 543322's PE Ratio compare to its peers?

The above table shows the PE ratio for 543322 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average32.5x
524735 Hikal
55.4x43.9%₹45.9b
524742 Caplin Point Laboratories
15.8x14.1%₹52.5b
25.1x44.6%₹42.3b
530019 Jubilant Pharmova
33.8x47.1%₹57.0b
543322 Glenmark Life Sciences
11.4x15.0%₹47.9b

Price-To-Earnings vs Peers: 543322 is good value based on its Price-To-Earnings Ratio (11.4x) compared to the peer average (32.5x).


Price to Earnings Ratio vs Industry

How does 543322's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.0%
n/an/an/a

Price-To-Earnings vs Industry: 543322 is good value based on its Price-To-Earnings Ratio (11.4x) compared to the Indian Pharmaceuticals industry average (25.6x)


Price to Earnings Ratio vs Fair Ratio

What is 543322's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

543322 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.4x
Fair PE Ratio25.8x

Price-To-Earnings vs Fair Ratio: 543322 is good value based on its Price-To-Earnings Ratio (11.4x) compared to the estimated Fair Price-To-Earnings Ratio (25.8x).


Share Price vs Fair Value

What is the Fair Price of 543322 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 543322 (₹389.95) is trading above our estimate of fair value (₹374.47)

Significantly Below Fair Value: 543322 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 543322 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹389.95
₹548.50
+40.7%
8.8%₹629.00₹500.00n/a4
Jan ’24₹420.45
₹562.25
+33.7%
7.2%₹629.00₹525.00n/a4
Dec ’23₹432.95
₹562.25
+29.9%
7.2%₹629.00₹525.00n/a4
Nov ’23₹437.50
₹562.25
+28.5%
7.2%₹629.00₹525.00n/a4
Oct ’23₹385.30
₹624.75
+62.1%
7.2%₹684.00₹560.00n/a4
Sep ’23₹439.95
₹624.75
+42.0%
7.2%₹684.00₹560.00n/a4
Aug ’23₹472.25
₹660.25
+39.8%
8.0%₹751.00₹620.00n/a4
Jul ’23₹442.05
₹662.75
+49.9%
7.8%₹751.00₹620.00n/a4
Jun ’23₹426.70
₹677.00
+58.7%
7.7%₹751.00₹640.00n/a3
May ’23₹474.85
₹677.00
+42.6%
7.7%₹751.00₹640.00n/a3
Apr ’23₹478.25
₹751.00
+57.0%
8.5%₹818.00₹665.00n/a3
Mar ’23₹458.35
₹772.67
+68.6%
4.7%₹818.00₹730.00n/a3
Feb ’23₹571.15
₹815.00
+42.7%
7.9%₹885.00₹730.00n/a3
Jan ’23₹631.05
₹821.67
+30.2%
8.1%₹885.00₹730.00₹420.453
Dec ’22₹610.30
₹821.67
+34.6%
8.1%₹885.00₹730.00₹432.953
Nov ’22₹625.10
₹821.67
+31.4%
8.1%₹885.00₹730.00₹437.503
Oct ’22₹674.40
₹790.00
+17.1%
7.6%₹850.00₹730.00₹385.302

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies